Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Vertebral Compression Fractures
Intervention: Device: OsseoFix Spinal Fracture Reduction System
Sponsor: Alphatec Spine, Inc.
Recruiting - verified March 2010
Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg; Drug: Peramivir 10 mg
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Conditions: Impetigo; Secondarily-infected Traumatic Lesions
Interventions: Drug: Linezolid; Drug: Retpamulin Ointment, 1%
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sinusitis
Intervention: Device: Stratus Microflow Ethmoid Spacer
Sponsor: Acclarent
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Back Pain
Interventions: Drug: placebo; Drug: tapentadol IR; Drug: oxycodone IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Not yet recruiting - verified February 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Euvolemic Hyponatremia
Interventions: Drug: lixivaptan; Drug: placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Procedure: thoracoscopic surgery; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: levonorgestrel; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole
Sponsors: American College of Surgeons; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Fetal Membranes, Premature Rupture
Interventions: Procedure: Retention of Cerclage; Procedure: Removal of Cerclage; Procedure: Removal vs. Retention of Cervical Cerclage
Sponsor: Obstetrix Medical Group
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: estramustine phosphate sodium; Drug: ketoconazole; Drug: prednisone; Drug: vinblastine; Radiation: strontium chloride Sr 89
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
All Locations ... United States » ... Georgia » ... Savannah 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
